Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Mladosievicova, Beata ^a   Urbanova, Dagmar ^a   Radvanska, Eva ^b   Slavkovsky, Peter ^a   Simkova, Iveta ^c  

^a Comenius University ^*  (Slovakia)

^b FACULTY HOSPITAL   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

Author keywords

Anthracyclines; Cardiotoxicity; Echocardiography; Natriuretic peptides; Survivors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ANALYZER; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; IMMUNOASSAY; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; ANTHRACYCLINES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; FEMALE; HEART INJURIES; HUMANS; INFANT; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS;

EID: 84867237480     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-86     Document Type: Article

References (29)

1. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM, BMJ 2009 339 4606 10.1136/bmj.b4606 19996459
2. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE, J Clin Oncol 2012 30 10 1042 1049 10.1200/JCO.2010.30.3404 22370326
3. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the Late Effects Surveillance System (LESS). Paulides M, Kremers A, Stöhr W, Bielack S, Jürgens H, Treuner J, Beck JD, Langer T, German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH), Pediatr Blood Cancer 2006 46 489 495 10.1002/pbc.20492 16333817
4. Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics. Mladosievicova B, Foltinova A, Luptak I, Petrasova H, Hulin I, Pediatr Cardiol 2001 22 478 482 10.1007/s002460010278 11894149
5. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA, J Clin Oncol 2001 19 191 196 11134212
6. Long-term results of the Pediatric Ooncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Childrens Oncology Group. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA, Leukemia 2010 24 2 355 370 10.1038/leu.2009.261 20016527
7. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institute Gustave Roussy. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, Villain E, de Vathaire F, Sidi D, Hartmann O, Br J Cancer 2004 91 1 37 44 10.1038/sj.bjc.6601904 15162142
8. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, N Engl J Med 2006 355 1572 1582 10.1056/NEJMsa060185 17035650
9. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP, N Engl J Med 1991 1324 808 815
10. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M, Circ Cardiovasc Imaging 2012 5 5 596 603 10.1161/CIRCIMAGING.112.973321 22744937
11. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, Clarke J, Thomas L, Eur J Echocardiogr 2011 12 12 945 952 10.1093/ejechocard/jer187 21965152
12. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, J Am Soc Echocardiogr 2005 18 12 1440 1463 10.1016/j.echo.2005.10.005 16376782
13. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, Mladosievicova B, J Exp Clin Cancer Res 2012 31 13 23 10.1186/1756-9966-31-13 22321767
14. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M, Eur Heart J 2006 27 330 337 16293638
15. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM, Clin Chem 2005 51 8 1405 1410 10.1373/clinchem.2005.050153 15932966
16. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M, Am J Clin Pathol 2008 130 688 695 10.1309/AJCPB66LRIIVMQDR 18854260
17. Role of biomarkers in chemotherapy-induced cardiotoxicity. Cardinale D, Sandri MT, Prog Cardiovasc Dis 2010 53 2 121 129 10.1016/j.pcad.2010.04.002 20728699
18. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A, Eur J Cancer 2007 43 13 1959 1966 10.1016/j.ejca.2007.06.012 17689066
19. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A, Eur J Heart Fail. 2005 7 87 93 10.1016/j.ejheart.2004.03.009 15642537
20. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Soker M, Kervancioglu M, Saudi Med J. 2005 26 1197 1202 16127512
21. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Koh E, Nakamura T, Takahashi H, Circ J 2004 68 163 167 10.1253/circj.68.163 14745153
22. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J, J Intern Med. 2002 251 228 234 10.1046/j.1365-2796.2002.00951.x 11886482
23. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Horacek JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J, Exp Oncol 2010 32 2 97 99 20693970
24. Accelerated atherosclerosis contributes to elevated global risk for premature symptomatic cardiovascular disease in survivors of childhood cancer. Kozlowski AM, Constine LS, Proukou C, Lipsitz SR, Miller TL, Vermilion RP, Rifai N, Proc Am Soc Clin Oncol 2003 abstr 3203
25. Correlation of plasma N-terminal probrain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Germanakis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, Vardas PE, Int J Cardiol 2006 108 212 215 10.1016/j.ijcard.2005.05.006 16290101
26. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer tretated with anthracyclines. Mavinkurve-Groothius AM, Groot-Loonen J, Bellersen L, Pourier MS, Feuth T, Bökkerink JP, Hoogerbrugge PM, Kapusta L, Pediatr Blood Cancer 2009 52 5 631 636 10.1002/pbc.21913 19127569
27. Long-term cardiac effects of treatment for childhood leukemia. Urbanova D, Urban L, Simkova I, Danova K, Mikuskova E, Mladosievicova B, Neoplasma 2010 57 2 179 183 10.4149/neo-2010-02-179 20099983
28. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Lipshultz SE, Landy DC, Lopez-Mitnik G, Lipsitz SR, Hinkle AS, Constine LS, French CA, Rovitelli AM, Proukou C, Adams MJ, Miller TL, J Clin Oncol 2012 30 10 1050 1057 10.1200/JCO.2010.33.7907 22393080
29. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F, Heart 2003 89 7 745 751 10.1136/heart.89.7.745 12807847